Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2023 |
| País: | España |
| Recursos: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositório: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10459.1/467621 |
| Acesso em linha: | https://doi.org/10.3390/jcm12237243 https://hdl.handle.net/10459.1/467621 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| id |
ES_cc0784a894ee9f02be5b6f77cc8b025c |
|---|---|
| oai_identifier_str |
oai:recercat.cat:10459.1/467621 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre StudySancho Saldaña, AgustínGil-Sánchez, AnnaGonzález Mingot, CristinaPeralta Moncusí, SilviaSolana Moga, M. JoséTorres Cabestany, PascualJuanes, AlbaQuibus, LauraRuiz, EmilioSanpedro, EduardoQuirant Sánchez, BibianaMartínez Cáceres, EvaRamo Tello, CristinaPresas Rodríguez, SilviaGarcía Rubio, SebatiánPardiñas Baron, BeatrizRamió Torrentà, LluísSotoca, JavierGonzález-Suarez, InésEichau, SaraPrieto-González, José M.Blasco Quilez, Maria RosarioSabín-Muñoz, JuliaSánchez-López, Antonio JoséLlorens Calatayud, GloriaCalles, CarmenPérez Sempere, ÁngelGarcés, MoisésCarmona, OlgaMoral, EsterHervás, J.V.Blanco, YolandaSola-Valls, NuriaTellez Lara, NievesForero, LucíaBrieva Ruiz, LuisMultiple SclerosisCOVID-19SARS-CoV-2DMTSeroprevalenceBackground: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. Keywords: COVID-19; DMT; Multiple Sclerosis; SARS-CoV-2; seroprevalence.MDPI2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.3390/jcm12237243https://hdl.handle.net/10459.1/467621reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/jcm12237243Journal Of Clinical Medicine, 2023, vol. 12, núm. 23, p. 7243cc-by (c) authors, 2023info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0oai:recercat.cat:10459.1/4676212026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| spellingShingle |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study Sancho Saldaña, Agustín Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| title_short |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_full |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_fullStr |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_full_unstemmed |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_sort |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| dc.creator.none.fl_str_mv |
Sancho Saldaña, Agustín Gil-Sánchez, Anna González Mingot, Cristina Peralta Moncusí, Silvia Solana Moga, M. José Torres Cabestany, Pascual Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant Sánchez, Bibiana Martínez Cáceres, Eva Ramo Tello, Cristina Presas Rodríguez, Silvia García Rubio, Sebatián Pardiñas Baron, Beatriz Ramió Torrentà, Lluís Sotoca, Javier González-Suarez, Inés Eichau, Sara Prieto-González, José M. Blasco Quilez, Maria Rosario Sabín-Muñoz, Julia Sánchez-López, Antonio José Llorens Calatayud, Gloria Calles, Carmen Pérez Sempere, Ángel Garcés, Moisés Carmona, Olga Moral, Ester Hervás, J.V. Blanco, Yolanda Sola-Valls, Nuria Tellez Lara, Nieves Forero, Lucía Brieva Ruiz, Luis |
| author |
Sancho Saldaña, Agustín |
| author_facet |
Sancho Saldaña, Agustín Gil-Sánchez, Anna González Mingot, Cristina Peralta Moncusí, Silvia Solana Moga, M. José Torres Cabestany, Pascual Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant Sánchez, Bibiana Martínez Cáceres, Eva Ramo Tello, Cristina Presas Rodríguez, Silvia García Rubio, Sebatián Pardiñas Baron, Beatriz Ramió Torrentà, Lluís Sotoca, Javier González-Suarez, Inés Eichau, Sara Prieto-González, José M. Blasco Quilez, Maria Rosario Sabín-Muñoz, Julia Sánchez-López, Antonio José Llorens Calatayud, Gloria Calles, Carmen Pérez Sempere, Ángel Garcés, Moisés Carmona, Olga Moral, Ester Hervás, J.V. Blanco, Yolanda Sola-Valls, Nuria Tellez Lara, Nieves Forero, Lucía Brieva Ruiz, Luis |
| author_role |
author |
| author2 |
Gil-Sánchez, Anna González Mingot, Cristina Peralta Moncusí, Silvia Solana Moga, M. José Torres Cabestany, Pascual Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant Sánchez, Bibiana Martínez Cáceres, Eva Ramo Tello, Cristina Presas Rodríguez, Silvia García Rubio, Sebatián Pardiñas Baron, Beatriz Ramió Torrentà, Lluís Sotoca, Javier González-Suarez, Inés Eichau, Sara Prieto-González, José M. Blasco Quilez, Maria Rosario Sabín-Muñoz, Julia Sánchez-López, Antonio José Llorens Calatayud, Gloria Calles, Carmen Pérez Sempere, Ángel Garcés, Moisés Carmona, Olga Moral, Ester Hervás, J.V. Blanco, Yolanda Sola-Valls, Nuria Tellez Lara, Nieves Forero, Lucía Brieva Ruiz, Luis |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| topic |
Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| description |
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. Keywords: COVID-19; DMT; Multiple Sclerosis; SARS-CoV-2; seroprevalence. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://doi.org/10.3390/jcm12237243 https://hdl.handle.net/10459.1/467621 |
| url |
https://doi.org/10.3390/jcm12237243 https://hdl.handle.net/10459.1/467621 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.3390/jcm12237243 Journal Of Clinical Medicine, 2023, vol. 12, núm. 23, p. 7243 |
| dc.rights.none.fl_str_mv |
cc-by (c) authors, 2023 info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/4.0 |
| rights_invalid_str_mv |
cc-by (c) authors, 2023 https://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869419639734272000 |
| score |
15,198674 |